The San Francisco Giants are taking a chance on a pitcher's recovery, signing a familiar face to their bullpen. But is this a risky move or a strategic investment?
The Giants have inked a one-year major league contract with right-handed pitcher Rowan Wick, a seasoned player who has undergone Tommy John surgery and is currently in the rehabilitation process. The deal includes a club option for the 2027 season, showing the team's long-term vision.
Wick's recent baseball journey has been a rollercoaster. After a successful stint with Japan's Yokohama DeNA BayStars, where he dominated with a 1.75 ERA in 87 2/3 innings, he's now returning to the States. And this is the part most people miss: despite his impressive performance overseas, Wick is not expected to take the mound this season due to his ongoing recovery.
The 33-year-old has had a varied career in the MLB. He started with the Chicago Cubs, where he became a reliable bullpen presence from 2019 to 2021 and even emerged as their closer in 2022, notching nine saves. But here's where it gets controversial—he lost some opportunities to the newly acquired David Robertson, sparking debates about the team's bullpen management.
Wick's journey took a turn in 2023, as he started the season in the minors and was eventually released by the Cubs. He moved on to the Braves and then the Blue Jays, but never found his way back to the big leagues. His Triple-A performance, with a 6.66 ERA, prompted his decision to try his luck in Japan's NPB.
The Giants have a history of signing injured pitchers, a strategy that has continued under Buster Posey's leadership. This offseason, they've also signed Sam Hentges, who is recovering from shoulder and knee surgery, and Jason Foley, who is coming off shoulder surgery. Both are potential candidates for the 60-day IL.
So, what's your take on the Giants' approach? Is signing injured players a smart move, or a gamble? Will Wick's recovery pay off for the Giants? Share your thoughts in the comments below!
